نتایج جستجو برای: raloxifene

تعداد نتایج: 1317  

2010
Caroline Jochems Ulrika Islander Malin Erlandsson Cecilia Engdahl Marie Lagerquist Inger Gjertsson Claes Ohlsson Rikard Holmdahl Hans Carlsten

BACKGROUND Collagen-induced arthritis (CIA) is an often-used murine model for human rheumatoid arthritis (RA). Earlier studies have shown potent anti-arthritic effects with the female sex hormone estradiol and the selective estrogen receptor modulator (SERM) raloxifene in CIA in DBA/1-mice. B10.Q-ncf1*/*mice are B10.Q mice with a mutated Ncf1 gene. In B10.Q-ncf1*/*mice, CIA develops as a chroni...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2002
Daniel C Kemp Peter W Fan Jeffrey C Stevens

Raloxifene, a selective estrogen receptor modulator used for the treatment of osteoporosis, undergoes extensive conjugation to the 6-beta- and 4'-beta-glucuronides in vivo. This paper investigated raloxifene glucuronidation by human liver and intestinal microsomes and identified the responsible UDP-glucuronosyltransferases (UGTs). UGT1A1 and 1A8 were found to catalyze the formation of both the ...

Journal: :Reumatizam 2005
Darko Kastelan Mirko Korsić

Osteoporosis, breast cancer and cardiovascular diseases are major health problems among postmenopausal women. Several pharmacologic options for treatment of osteoporosis are available, including hormone replacement therapy (HRT), bisphosphonates, calcitonin and selective estrogen receptor modulators. However, longterm HRT is associated with unwanted side effects such as vaginal bleeding and bre...

2016
María E. Fernández-Suárez Joan C. Escolà-Gil Oscar Pastor Alberto Dávalos Francisco Blanco-Vaca Miguel A. Lasunción Javier Martínez-Botas Diego Gómez-Coronado

Selective estrogen receptor modulators (SERMs) are widely prescribed drugs that alter cellular and whole-body cholesterol homeostasis. Here we evaluate the effect of SERMs on the macrophage-specific reverse cholesterol transport (M-RCT) pathway, which is mediated by HDL. Treatment of human and mouse macrophages with tamoxifen, raloxifene or toremifene induced the accumulation of cytoplasmic ves...

Journal: :Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2010
Mihoko Matsumura Tsuyoshi Monden Yuki Nakatani Hiroaki Shimizu Nozomi Domeki Kazunori Yanagi Shiori Ikeda Yoshiaki Kawagoe Kikuo Kasai

OBJECTIVE Our aim was to investigate the effect of 1-year treatment with raloxifene, a selective estrogen receptor modulator, on plasma lipid profiles in Japanese postmenopausal type 2 diabetic patients. SUBJECTS AND METHODS A total of 43 Japanese women with postmenopausal osteoporosis and type 2 diabetes with serum low-density lipoprotein cholesterol (LDL-C) <3.59 mmol/l, serum triglyceride ...

Journal: :American journal of physiology. Cell physiology 2000
M E Nuttall G B Stroup P W Fisher D P Nadeau M Gowen L J Suva

Raloxifene and idoxifene are selective estrogen receptor modulators (SERMs) that exhibit tissue-specific agonist or antagonist properties via interactions with the estrogen receptor (ER). Both compounds are similarly osteoprotective in the ovariectomized rat in vivo as assessed by measurement of bone mineral density, urinary pyridinium cross-links, and serum osteocalcin, suggesting a similar me...

2013
Anand Kumar Kushwaha Parameswara Rao Vuddanda Priyanka Karunanidhi Sanjay Kumar Singh Sanjay Singh

Raloxifene hydrochloride (RL-HCL) is an orally selective estrogen receptor modulator (SERM) with poor bioavailability of nearly 2% due to its poor aqueous solubility and extensive first pass metabolism. In order to improve the oral bioavailability of raloxifene, raloxifene loaded solid lipid nanoparticles (SLN) have been developed using Compritol 888 ATO as lipid carrier and Pluronic F68 as sur...

Journal: :Cancer prevention research 2010
Victor G Vogel Joseph P Costantino D Lawrence Wickerham Walter M Cronin Reena S Cecchini James N Atkins Therese B Bevers Louis Fehrenbacher Eduardo R Pajon James L Wade André Robidoux Richard G Margolese Joan James Carolyn D Runowicz Patricia A Ganz Steven E Reis Worta McCaskill-Stevens Leslie G Ford V Craig Jordan Norman Wolmark

The selective estrogen-receptor modulator (SERM) tamoxifen became the first U.S. Food and Drug Administration (FDA)-approved agent for reducing breast cancer risk but did not gain wide acceptance for prevention, largely because it increased endometrial cancer and thromboembolic events. The FDA approved the SERM raloxifene for breast cancer risk reduction following its demonstrated effectiveness...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1997
T A Grese J P Sluka H U Bryant G J Cullinan A L Glasebrook C D Jones K Matsumoto A D Palkowitz M Sato J D Termine M A Winter N N Yang J A Dodge

Interaction of the estrogen receptor/ligand complex with a DNA estrogen response element is known to regulate gene transcription. In turn, specific conformations of the receptor-ligand complex have been postulated to influence unique subsets of estrogen-responsive genes resulting in differential modulation and, ultimately, tissue-selective outcomes. The estrogen receptor ligands raloxifene and ...

2016
Kaye A. Griffiths Mark A. Sader Michael R. Skilton Jason A. Harmer David S. Celermajer

OBJECTIVES We sought to assess the effects of raloxifene, a selective estrogen receptor modulator, on arterial physiology and biology in postmenopausal women with coronary artery disease (CAD). BACKGROUND Raloxifene improves endothelial function and markers of vascular health in vitro in experimental animals and in healthy postmenopausal women. In women whose arteries are affected by advanced a...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید